Controlled siRNA Release of Nanopolyplex for Effective Targeted Anticancer Therapy in Animal Model
Jingchao Jia,Jing Yang,Leimin Qian,Biao Zhou,Xiaodong Tang,Shuanghai Liu,Li Wu,Jifeng Chen,Yuting Kuang
DOI: https://doi.org/10.2147/ijn.s443636
IF: 7.033
2024-02-08
International Journal of Nanomedicine
Abstract:Jingchao Jia, 1, 2, &ast Jing Yang, 3, &ast Leimin Qian, 2 Biao Zhou, 2 Xiaodong Tang, 2 Shuanghai Liu, 2 Li Wu, 4 Jifeng Chen, 5 Yuting Kuang 1 1 Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China; 2 Department of General Surgery, Jiangyin Hospital Affiliated to Nantong University, Wuxi, People's Republic of China; 3 Jiangnan University Medical Center, Wuxi, People's Republic of China; 4 Department of Pharmaceutics, People's Hospital of Shanggao, Yichun, People's Republic of China; 5 The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Jinan University, Guangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yuting Kuang, Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China, Email Jifeng Chen, The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Jinan University, Guangzhou, People's Republic of China, Email Introduction: Spatiotemporally controlled release of siRNA for anti-tumor therapy poses significant challenges. Near-infrared (NIR) light, known for its exceptional tissue penetration and minimal tissue invasiveness, holds promise as a viable exogenous stimulus for inducing controlled siRNA release in vivo. However, the majority of light-responsive chemical bonds exhibit absorption wavelengths in the ultraviolet (UV) or short-wavelength visible light range. Methods: To achieve NIR-controlled siRNA release, the study synthesized a UV-sensitive triblock copolymer cRGD-poly(ethylene glycol)- b -poly(aspartic acid ester-5-(2'-(dimethylamino)ethoxy)-2-nitrobenzyl alcohol)- b -polyphenylalanine, abbreviated as cRGD-PEG-PAsp(EDONB)-PPHE. This copolymer is composed of a cRGD-capped PEG block (cRGD-PEG), a poly(aspartate) block modified with cationic moieties through UV-cleavable 2-nitrobenzyl ester bonds [PAsp(EDONB)], and a hydrophobic polyphenylalanine block (PPHE). The cationic amphiphilic polymer cRGD-PEG-PAsp(EDONB)-PPHE can assemble with hydrophobic upconversion nanoparticles (UCNPs) to form a cationic micelle designated as T-UCNP, which subsequently complexes with siRNA to create the final nanopolyplex T-si/UCNP. siRNA-PLK1 was employed to prepare T-PLK1/UCNP nanopolyplex for anti-tumor therapy. Results: T-PLK1/UCNP not only exhibited outstanding tumor cell targeting through cRGD modification but also achieved 980 nm NIR-controlled PLK1 gene silencing. This was achieved by utilizing the encapsulated UCNPs to convert NIR into UV light, facilitating the cleavage of 2-nitrobenzyl ester bonds. As a result, there was a significant suppression of tumor growth. Conclusion: The UCNPs-encapsulated nanopolyplex T-si/UCNP, capable of co-delivering siRNA and UCNPs, enables precise NIR-controlled release of siRNA at the tumor site for cancer RNAi therapy. This nanopolyplex can enhance the controllability and safety of RNAi therapy for tumors, and it also holds the potential to serve as a platform for achieving controlled release and activation of other drugs, such as mRNA and DNA. Keywords: NIR-controlled siRNA release, nanopolyplex, UCNPs, anti-tumor therapy Small interfering RNA (siRNA)-based therapeutics represent a highly promising approach for cancer therapy. 1–3 However, the lack of safe and controllable siRNA delivery vehicles has significantly impeded its application and advancement. 4,5 Currently, only a limited number of siRNA drugs have obtained clinical approval from the FDA, and they are exclusively indicated for the treatment of hepatic disorders. 6,7 This is due to the challenge of achieving specific siRNA delivery exclusively to non-hepatic tissues. 8 Even siRNA drugs with excellent targeting properties are predominantly metabolized in the liver, leading to adverse effects. 9 Therefore, a controllable delivery carrier is crucial for triggering siRNA function at the pathological site, thereby expanding the effective application of siRNA therapy to a broader range of diseases, including cancer. Until now, various controlled-release strategies have been employed in the development of siRNA delivery carriers, including light irradiation, 10 pH response, 11 enzymatic hydrolysis, 12 and redox reactions. 13 Among these strategies, light irradiation, as an external stimulus, has proven to be an effective approach for achieving precise spatiotemporal control over siRNA release.<s -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology